DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm

The owner of DIAGOMICS has sold the company to ZytoMax GmbH.

Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.

Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.

Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.

Service

M&A sell-side

Parties

“DIAGOMICS has reached a strategic turning point given its rapid and exponential growth. To strengthen our market position and continue to offer innovative and quality products, DIAGOMICS is joining the ZytoMax group. Our shared values, such as scientific expertise and customer proximity, contributed to this choice.”

Gwénola Tanneau

Founder and CEO, DIAGOMICS

Talk to the deal team

Xavier Auvergnat

Partner

Toulouse, France
Oaklins France

View profile Get in touch

Related deals

Valmiermuižas Alus has been acquired by Cēsu Alus

Private Equity | Food & Beverage

Valmiermuižas Alus has been acquired by Cēsu Alus

Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.

Learn more

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more

Armira has signed an agreement to acquire a majority stake in Viabus

Private Equity | Consumer & Retail

Armira has signed an agreement to acquire a majority stake in Viabus

Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.

Learn more